Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand
Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2
AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im
In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent
Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.